Due to the inclusion of the International Sales Index in last month’s issue, IBO was unable to publish the results of the Life Science Sales Index for the second quarter. Here we present the results for that Index, as well as quarterly financial information for Index companies that not been covered in a previous issue. With all 17 companies in IBO’s Life Science Sales Index having reported their calendar year 2007 half-year results, the Index grew 12.8% in the second quarter to $2,146 million. Operating profits soared 19.6% to $299 million, leading operating margin up 80 basis points to 14.0% of sales. Revenue for Becton Dickinson and Company’s BD Biosciences division rose 12.9%, including 5.5% growth due to currency effects, in the fiscal third quarter to $257.6 million to represent 16% of Becton Dickinson’s total revenues. Adjusted operating revenue improved 11.9% to $65.5 million, and operating margins climbed 250 basis points to 25.4% of sales, due to increased revenue growth and lower operating costs. US sales grew 6.9% to $109.6 million, while international sales increased 17.7% to $148.1 million. Growth came primarily from sales of flow cytometry instruments, reagents and bioprocessing systems. Discovery Labware, Immunocytometry Systems and Pharmingen sales rose 8.4%, 16.6% and 8.4% to make up 27%, 56% and 17% of BD Bioscience revenues, respectively. On a currency-neutral basis, Discovery Labware, Immunocytometry Systems and Pharmingen sales grew 6.2%, 13.0% and 5.5%, respectively. In its quarterly conference call, the company noted the rapid growth of over 40% a year for Discovery Labware’s bioprocessing business. The company forecasts that BD Biosciences revenues will grow approximately 11% this fiscal year. Caliper Life Sciences announced a 45.2% jump in second quarter revenues to $35.3 million and cut its adjusted operating loss in half to $3.5 million, primarily due to the acquisition of Xenogen (see IBO 2/15/06), as well as strong sales of the microfluidics product lines. Product revenue grew 70.8% to $21.0 million, and service revenue improved 66.0% to $8.9 million, while license fees and contract revenue declined 19.6% to $5.3 million. Revenue growth was partially offset by declining sales of liquid handling and automation products, which were negatively impacted by increased competition. Lower license and contract revenues were affected by the timing of certain license agreements and are expected to improve over the second half of 2007. Tecan reported a 2.2% decline in revenues for the first half of 2007 to CHF 196.2 million ($160.2 million = CHF 1.22 = $1) from CHF 200.7 million ($158.0 million = CHF 1.27 = $1). Revenue growth was adversely affected by the cancellation of a development project, amounting to CHF 6.4 million ($5.2 million). Starting with this reporting period, Tecan is reporting sales for three separate business segments: Components & Detection, Liquid Handling & Robotics and Sample Management, which accounted for 28%, 62% and 10% of sales, respectively. Sales to America and Europe declined 2.8% and 4.2% to make up 33% and 63% of sales, respectively, while sales to Asia improved 54%. Operating profit improved 7.4% to CHF 24.8 million ($20.2 million) and operating margin climbed 112 basis points to 12.65% of sales.